Loading
A phase 2 trial of Tucatinib, Trastuzumab and Fulvestrant in endometrial cancer, cervical cancer, biliary tract cancer and non-small-cell lung cancer, run by Seagen, a wholly owned subsidiary of Pfizer, active and no longer recruiting.
Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations is a phase 2 interventional study registered as NCT04579380 by Seagen, a wholly owned subsidiary of Pfizer, with 217 participants enrolled, started 2021-01-11 and due to reach its primary completion in 2023-11-01. Interventions recorded: tucatinib, trastuzumab and fulvestrant. Results have been posted on the registry.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
217 enrolled.
90% CI 7.9 to 56.4; Figures from the ClinicalTrials.gov results section (first posted 2024-11-13), not from a publication · 90% CI 4.7 to 28.0 · 90% CI 30.8 to 63.0 · 90% CI 1.4 to 23.1 · 90% CI 0.4 to 33.9 · 90% CI 11.1 to 38.3 · 90% CI 0.0 to 20.6 · 90% CI 26.9 to 58.2 · 90% CI 2.9 to 24.6
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Confirmed Objective Response Rate (cORR) as Assessed by Investigatorprimary | Tucatinib+Trastuzumab (Cohort 1) | 11 | 27.3% | - | - | link |
| Tucatinib+Trastuzumab (Cohort 2) | 30 | 13.3% | ||||
| Tucatinib+Trastuzumab (Cohort 3) | 30 | 46.7% | ||||
| Tucatinib+Trastuzumab (Cohort 4) | 25 | 8% | ||||
| Tucatinib+Trastuzumab (Cohort 5) | 12 | 8.3% | ||||
| Tucatinib+Trastuzumab (Cohort 6) | 31 | 22.6% | ||||
| Tucatinib+Trastuzumab (Cohort 7) | 13 | 0% | ||||
| Tucatinib+Trastuzumab+ Fulvestrant (Cohort 8) | 31 | 41.9% | ||||
| Tucatinib+Trastuzumab (Cohort 9) | 29 | 10.3% |
Shares HER2 tyrosine kinase inhibitors, Tucatinib, Pfizer (incl. Seagen), Trastuzumab and the tag pipeline.
Shares HER2 tyrosine kinase inhibitors, Tucatinib, Trastuzumab, Monoclonal antibodies and the tag pipeline.
Shares HER2 tyrosine kinase inhibitors, Tucatinib, Fulvestrant, Pfizer (incl. Seagen) and the tag pipeline.
Shares HER2-mutant non-small-cell lung cancer, Pfizer (incl. Seagen), Endometrial cancer, Non-small-cell lung cancer and the tag pipeline.
Shares HER2 tyrosine kinase inhibitors, Tucatinib, Monoclonal antibodies, Small-molecule kinase inhibitors and the tag pipeline.
Shares HER2-mutant non-small-cell lung cancer, Monoclonal antibodies, Small-molecule kinase inhibitors, Non-small-cell lung cancer and the tag pipeline.
Shares Endometrial cancer, Biliary tract cancer (cholangiocarcinoma), Cervical cancer and the tag pipeline.
Shares Endometrial cancer, Biliary tract cancer (cholangiocarcinoma), Non-small-cell lung cancer and the tag pipeline.